Abstract 1877P
Background
After completion of curative cancer treatment patients enter the re-entry phase, which is characterized by the difficult task to pick up life again. In the re-entry patients face existential concerns, besides physical and psychosocial concerns. Finding meaning and purpose in this new situation may help in dealing with existential concerns. More insight is needed in the existential concerns and the meaning-making process in order to support patients in the re-entry phase.
Methods
We conducted 6 focus groups with 16 patients (5 patients with melanoma and 11 with breast cancer) during the re-entry phase, defined as the point from completion of treatment (after surgical treatment and adjuvant systemic treatment, except for hormonal therapy) up to 18 months in remission. A thematic content analysis was performed by two researchers.
Results
In general, patients experienced existential concerns regarding their worldview, inner posture, values and the future. In addition, patients with melanoma struggled with trust and responsibility for their health; patients with breast cancer struggled with relationships and identity. Outcomes of the meaning-making process identified were: meaning is affected and gives distress, existing sources of meaning are helpful, search for meaning or new meaning has been found. These outcomes were found at the beginning as well as further into the re-entry, however during the re-entry the focus of the meaning-making process shifted from the disease to (picking up) life.
Conclusions
The transition from being a patient to picking up daily life in the re-entry phase involves dealing with existential concerns causing distress. Patients use existing sources of meaning, search for new meaning or have found new meaning in order to deal with these existential concerns and distress. A meaning-centered intervention increasing patients awareness of their personal sources of meaning might strengthen their meaning-making process and can help in dealing with existential concerns.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Visser and L. Post.
Funding
Novartis b.v.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands
Presenter: Ellis Slotman
Session: Poster session 05
1595P - Incidence and characterization of end-of-life (EoL) systemic anticancer therapy (SACT) in melanoma patients (pts): A monocentric experience
Presenter: Silvia Buriolla
Session: Poster session 05
1596P - Exploring the economic impact of palliative care in oncology at the end of life
Presenter: Sarah Gomes
Session: Poster session 05
1597P - Improving in-hospital end-of-life care (EOLC) for oncology patients in a tertiary cancer centre
Presenter: Conor Moloney
Session: Poster session 05
1598P - Differences in referral patterns to the palliative care team among specialized physicians in patients with terminal cancer
Presenter: Hyun Jeong Shim
Session: Poster session 05
1599P - Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study
Presenter: Alessandro Leonetti
Session: Poster session 05
1600P - Sarcopenia, depression, and poor health perception among cancer patients registered in an oncology center in Pakistan
Presenter: Sobia Yaqub
Session: Poster session 05
1601P - Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy
Presenter: Gurkan Guner
Session: Poster session 05
1602P - Simulation training for compassionate extubation in the pediatric intensive care unit
Presenter: Nicole Fernandez
Session: Poster session 05
1603P - The ability of the LACE index to predict 30-day readmissions in oncology patients
Presenter: Burcu Ulas Kahya
Session: Poster session 05